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Neurological manifestations as the
predictors of severity and mortality in
hospitalized individuals with COVID-19: a
multicenter prospective clinical study
Man Amanat1, Nima Rezaei2,3,4, Mehrdad Roozbeh5, Maziar Shojaei6, Abbas Tafakhori7, Anahita Zoghi6,
Ilad Alavi Darazam8, Mona Salehi1, Ehsan Karimialavijeh9, Behnam Safarpour Lima6, Amir Garakani10,11,
Alexander Vaccaro12 and Mahtab Ramezani13*

Abstract
Backgrounds: The reports of neurological symptoms are increasing in cases with coronavirus disease 2019 (COVID19). This multi-center prospective study was conducted to determine the incidence of neurological manifestations
in hospitalized cases with COVID-19 and assess these symptoms as the predictors of severity and death.
Methods: Hospitalized males and females with COVID-19 who aged over 18 years were included in the study. They
were examined by two neurologists at the time of admission. All survived cases were followed for 8 weeks after
discharge and 16 weeks if their symptoms had no improvements.
Results: We included 873 participants. Of eligible cases, 122 individuals (13.97%) died during hospitalization. The
most common non-neurological manifestations were fever (81.1%), cough (76.1%), fatigue (36.1%), and shortness of
breath (27.6%). Aging, male gender, co-morbidity, smoking, hemoptysis, chest tightness, and shortness of breath
were associated with increased odds of severe cases and/or mortality. There were 561 (64.3%) cases with smell and
taste dysfunctions (hyposmia: 58.6%; anosmia: 41.4%; dysguesia: 100%). They were more common among females
(69.7%) and non-smokers (66.7%). Hyposmia/anosmia and dysgeusia were found to be associated with reduced
odds of severe cases and mortality. Myalgia (24.8%), headaches (12.6%), and dizziness (11.9%) were other common
neurological symptoms. Headaches had negative correlation with severity and death due to COVID-19 but myalgia
and dizziness were not associated. The cerebrovascular events (n = 10) and status epilepticus (n = 1) were other
neurological findings. The partial or full recovery of smell and taste dysfunctions was found in 95.2% after 8 weeks
and 97.3% after 16 weeks. The parosmia (30.9%) and phantosmia (9.0%) were also reported during 8 weeks of
follow-up. Five cases with mild headaches and 5 cases with myalgia were reported after 16 weeks of discharge. The
demyelinating myelitis (n = 1) and Guillain-Barré syndrome (n = 1) were also found during follow-up.
Conclusion: Neurological symptoms were found to be prevalent among individuals with COVID-19 disease and
should not be under-estimated during the current pandemic outbreak.
Keywords: SARS-CoV-2, Anosmia, Headache, Neurology, Seizure, Stroke
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Introduction
The novel virus from the coronaviridae family termed as
severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) was first discovered in December, 2019 after
many pneumonia cases with unknown cause were identified in Wuhan, China [1]. The SARS-CoV-2 is a βcoronavirus which is an enveloped virus with helical nucleocapsid and non-segmented positive ribonucleic acid
that can infect mammals [2–5]. The World Health
Organization (WHO) declared coronavirus disease 2019
(COVID-19) as a pandemic outbreak on March 11th,
2020. Over 80 million confirmed cases and about 2 million deaths due to COVID-19 were recorded until the
end of 2020 [6].
Several non-respiratory symptoms have been reported
in individuals with COVID-19. The reports of neurological features are increasing but few large sample-sized
studies reported the incidence of neurological disorders
in people with COVID-19. Myalgia, headaches, and loss
of smell (anosmia) and taste (dysgeusia) sensations are
common neurological findings of the disease [7–9]. Recent studies showed that SARS-CoV-2 could manifest as
life-threatening neurological conditions including ischemic stroke, subarachnoid hemorrhage, status epilepticus,
and acute demyelinating encephalomyelitis [10–13].
Neurological symptoms were also reported in epidemic
outbreaks of other coronaviruses including SARS-CoV
and the Middle East respiratory syndrome (MERS)-CoV
[14, 15]. The direct invasion of coronaviruses to the nervous system and over-production of pro-inflammatory
cytokines could be the plausible underlying mechanisms
[16]. This study aimed to determine the incidence of
neurological manifestations in hospitalized cases with
COVID-19 and assess these symptoms as predictors of
severity and death.
Methods
Study design and participants

This was a prospective hospital-based cohort study conducted in Loghman, Imam Hossein, and Imam Khomeini hospitals, the three major referral hospitals in
Tehran province, Iran. Males and females aged above 18
years who were diagnosed with COVID-19 based on
WHO recommendations [17] were included in the
study. The sterile nasopharyngeal swabs were inserted in
one nostril of each participant. The collected specimens
were placed into tubes containing viral transport
medium; stored at 4o C to 8o C and were sent to laboratories within 12 h. The positive results of real-time
reverse-transcription polymerase chain reaction (RTPCR) assay using a SARS-CoV-2 nucleic acid detection
kit (PCR Fluorescence Probing of Sansure Biotech,
Changsha, China) could confirm COVID-19. The exclusion criteria were the presence of other respiratory
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infections (e.g. tuberculosis), loss of competence and no
access to surrogates, and withdrawal of consent.
The ethics committee of Shahid Beheshti University of
Medical Sciences approved the study. The protocol was
explained to all participants and if they lacked decisionmaking capacity, their legal surrogates were informed
about the study. The printed protocol was also given. It
was explained that participation in the study was optional and the identity information would remain confidential and not published. Written informed consent
was obtained before the initiation of the study.
Data collection

All eligible inpatients were interviewed and the demographic characteristics including gender, age, smoking
status, and co-morbidities were recorded. Participants
were examined and chest computed tomography (CT)
was performed in all cases. The laboratory tests included
cell blood count, quantitative C-reactive protein (CRP),
lactate dehydrogenase (LDH), and procalcitonin. The severity of COVID-19 was determined using American
Thoracic Society recommendations for communityacquired pneumonia [18].
To assess neurological manifestations, two neurologists with at least 5 years of experience took a detailed
history and examined all participants. Any disagreement
was resolved by discussion with each other or consultation with another neurologist. Headaches were known
to be associated with COVID-19 if they fulfilled the criteria for ‘Headache attributed to systemic viral infection’
according to the International Classification of Headache
Disorders [19]. Brain CT and/or magnetic resonance imaging (MRI), electroencephalography (EEG), electromyography and nerve conduction velocity (EMG-NCV),
as well as cerebrospinal fluid (CSF) analysis were conducted if clinically indicated. Smell and taste dysfunctions were assessed in cases using a self-reporting tool.
The National Institute of Health stroke scale (NIHSS)
was used to evaluate the severity of ischemic stroke. The
NIHSS was designed to objectively quantify neurological
impairments in stroke and consisted of 11 items [20].
Each item can be scored from 0 to 4 and the total possible scores ranged from 0 to 42. Neurological impairments can be divided into four categories using NIHSS:
a. mild (0–4), b. moderate (5–15), c. Moderate to severe
(16–20), and d. severe (21–42). The intracerebral
hemorrhage (ICH) score was also calculated in participants with ICH. This is a clinical grading scale using
Glasgow Coma Scale, age, the presence of infratentorial
origin, ICH volume, and the presence of intraventricular
hemorrhage to predict the ICH mortality [21]. The total
score ranged from 0 to 6.
Most included cases were followed for 8 weeks after
discharge from hospital to assess the course of their
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neurological manifestations. If their neurological symptoms were persistent, they were followed for further
8 weeks. Cellphone and telephone numbers of each participant were recorded and they were interviewed via
phone once per 4 weeks by a neurologist. If cases reported any new-onset neurological complaints, they
would be asked to visit the hospital for further assessments. A phone number was also given to participants
so physical complaints could be reported as soon as possible. Participants were asked to go to the emergency department if serious events occurred.
Statistical analysis

Continuous variables were presented as means with
standard deviation (SD) and compared between groups
using independent sample t test. Categorical variables
were described as numbers with percentages and compared between groups using Pearson’s chi-squared test.
To more rigorously assess the predictors of severity and
death due to COVID-19, odds ratio (OR) with 95% confidence interval (CI) was calculated using univariate and
multivariate logistic regression.. The calculated ORs of
neurological manifestations were adjusted for gender,
age, smoking status, and co-morbidity. All analyses were
conducted using the IBM SPSS Software version 25.0
(SPSS Inc., Chicago, IL). Two sided significance testing

Fig. 1 The study diagram
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was performed and p-values < 0.05 were considered
significant.

Results
Participants

The study was initiated on April 7, 2020 when the clinical characteristics of the first hospitalized participant
were assessed. The follow-up of survived cases lasted
until November 18, 2020. Primary screening was performed on 1269 inpatients and 873 cases were included
in the study (Fig. 1). Of eligible participants, 122 individuals died during hospitalization (case fatality rate:
13.97%) and 751 cases were discharged in 11.41 ± 6.20
(mean ± SD) days. There were 62 participants who were
lost to follow-up and 689 individuals completed the
study.
Non-neurological characteristics

The demographic clinical features of included cases during hospitalization were presented in Table 1. There
were 551 males (63.7%) and 317 females (36.3%). The
mean ± SD age of participants was 60.71 ± 18.14 years
and 459 individuals (52.6%) aged over 60 years. The
most common non-neurological manifestations were
fever (708/873, 81.1%), cough (664/873, 76.1%), fatigue
(315/873, 36.1%), and shortness of breath (241/873,
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Table 1 Demographic characteristics and non-neurological clinical manifestations of participants
Clinical features

Age (mean ± SD)

Total

Disease severity

N = 873

Non-severe (N = 574)

Severe (N = 299)

P-value

No
(N = 751)

Death outcome
Yes
(N = 122)

60.71 ± 18.14

58.57 ± 17.95

64.82 ± 17.95

0.00

58.12 ± 17.59

76.68 ± 12.46

400 (53.3)

14 (11.5)

0.00

351 (46.7)

108 (88.5)

280 (37.3)

37 (30.3)

≤60 years

414 (47.4)

296 (51.6)

118 (39.5)

> 60 years

459 (52.6)

278 (48.4)

181 (60.5)

317 (36.3)

223 (38.9)

94 (31.4)

Pvalue
0.00

0.00

Gender
Female
Male

556 (63.7)

351 (61.1)

205 (68.6)

0.03

471 (62.7)

85 (69.7)

0.16

Smoking

137 (15.7)

77 (13.4)

60 (20.1)

0.01

101 (13.4)

36 (29.5)

0.00

Co-morbidities

512 (58.6)

318 (55.4)

194 (64.9)

0.01

417 (55.5)

95 (77.9)

0.00

Fever

708 (81.1)

472 (82.2)

236 (78.9)

0.23

614 (81.8)

94 (77.0)

0.21

Cough

664 (76.1)

429 (74.7)

235 (78.6)

0.21

572 (76.2)

92 (75.4)

0.91

Fatigue

315 (36.1)

205 (35.7)

110 (36.8)

0.76

264 (35.2)

51 (41.8)

0.16

Shortness of breath

241 (27.6)

121 (21.1)

120 (40.1)

0.00

154 (20.5)

87 (71.3)

0.00

Sputum production

156 (17.9)

94 (16.4)

62 (20.7)

0.11

133 (17.7)

23 (18.9)

0.80

Chills

101 (11.6)

72 (12.5)

29 (9.7)

0.22

88 (11.7)

13 (10.7)

0.88

Sore throat

97 (11.1)

58 (10.1)

39 (13.0)

0.21

84 (11.2)

13 (10.7)

1.00

Chest tightness

96 (11)

39 (6.8)

57 (19.1)

0.00

70 (9.3)

26 (21.3)

0.00

Nausea

94 (10.8)

64 (11.1)

30 (10.0)

0.65

81 (10.8)

13 (10.7)

1.00

Vomiting

36 (4.1)

26 (4.5)

10 (3.3)

0.48

32 (4.3)

4 (3.3)

0.80

Diarrhea

32 (3.7)

23 (4.0)

9 (3.0)

0.57

28 (3.7)

3 (2.5)

1.00

Hemoptysis

54 (6.2)

20 (3.5)

34 (11.4)

0.00

40 (5.3)

14 (11.5)

0.01

Rhinorrhea

49 (5.6)

26 (4.5)

23 (7.7)

0.06

40 (5.3)

9 (7.4)

0.39

Nasal congestion

24 (2.7)

15 (2.6)

9 (3.0)

0.83

23 (3.1)

1 (0.8)

0.23

Conjunctival congestion

4 (0.5)

2 (0.3)

2 (0.7)

0.61

4 (0.5)

0 (0)

1.00

Categorical variables are presented as numbers (percentages); SD: standard deviation

Table 2 The laboratory data of participants
Laboratory data

Leukopenia < 3500/mm3
3

Total

Disease severity

Death outcome

N = 873

Non-severe (N = 574)

Severe (N = 299)

P-value

No
(N = 751)

Yes
(N = 122)

39 (4.5)

20 (3.5)

19 (6.4)

0.06

30 (4.0)

9 (7.4)

Pvalue
0.09

Leukocytosis > 11,000/mm

167 (19.1)

108 (18.8)

59 (19.7)

0.79

135 (18)

32 (26.2)

0.03

Neutropenia < 1500/mm3

17 (1.9)

12 (2.1)

5 (1.7)

0.80

14 (1.9)

3 (2.5)

0.72

Neutrophilia > 8000/mm3

291 (33.3)

168 (29.3)

123 (41.1)

0.00

222 (29.6)

69 (56.6)

0.00

Lymphocytopenia < 1000/mm3

434 (49.7)

270 (47.0)

164 (54.8)

0.03

364 (48.5)

70 (57.4)

0.08

Lymphocytosis > 4000/mm

17 (1.9)

11 (1.9)

6 (2.0)

1.00

15 (2.0)

2 (1.6)

1.00

Thrombocytopenia < 100,000/mm3

65 (7.4)

39 (6.8)

26 (8.7)

0.34

56 (7.5)

9 (7.4)

1.00

Thrombocytosis > 450,000/mm

11 (1.3)

7 (1.2)

4 (1.3)

1.00

11 (1.5)

0 (0)

0.38

Elevated LDH > 245 U/liter

316 (36.2)

176 (30.7)

140 (46.8)

0.00

217 (28.9)

99 (81.1)

0.00

3

3

Elevated CRP > 10 mg/liter

542 (62.1)

339 (59.1)

203 (67.9)

0.01

433 (57.7)

109 (89.3)

0.00

Elevated Procalcitonin > 0.5 ng/ml

63 (7.2)

30 (5.2)

33 (11.0)

0.00

37 (4.9)

26 (21.3)

0.00

Categorical variables are presented as numbers (percentages); LDH lactate dehydrogenase, CRP C-reactive protein
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27.6%). Our analysis showed that aging (severity: OR:
1.020, 95%CI: 1.012 to 1.028; death: OR: 1.08, 95%CI:
1.06 to 1.99), male gender (severity: OR: 1.38, 95%CI:
1.03 to 1.86), presence of co-morbidity (OR: 1.43,
95%CI: 1.11 to 1.98; death: OR: 2.81, 95%CI: 1.79 to
4.42), smoking (severity: OR: 1.62, 95%CI: 1.11 to 2.34;
death: 2.69, 95%CI: 1.73 to 4.18), hemoptysis (severity:
OR: 3.55, 95%CI: 2.01 to 6.28; death: OR: 2.30, 95%CI:
1.21 to 4.36), chest tightness (severity: OR: 3.23, 95%CI:
2.09 to 5.00; death: OR: 2.63, 95%CI: 1.60 to 4.32), and
shortness of breath (severity: OR: 2.51, 95%CI: 1.84 to
3.41; death: OR: 9.61, 95%CI: 6.25 to 14.92) were associated with increased odds of severity and/or death in
participants.
The most common laboratory abnormalities were elevated CRP (542/873, 61.2%), lymphocytopenia (434/873,
49.7%), elevated LDH (316/873, 35.7%), and neutrophilia
(291/873, 33.3%) (Table 2). The statistical analysis
showed that the elevated procalcitonin (severity: OR:
2.26, 95%CI: 1.35 to 3.78; death: OR: 5.40; 95%CI: 3.12
to 9.34), elevated LDH (severity: OR: 1.99, 95%CI: 1.49
to 2.65; death: OR: 10.63; 95%CI: 6.53 to 17.24), neutrophilia (severity: OR: 1.68, 95%CI: 1.26 to 2.26; death: OR:
3.10; 95%CI: 2.09 to 4.58), elevated CRP (severity: OR:
1.46, 95%CI: 1.09 to 1.96; death: OR: 6.17; 95%CI: 3.40
to 11.11), leukocytosis (death: OR: 1.62, 95%CI: 1.04 to
2.53), and lymphocytopenia (severity: OR: 1.36, 95%CI:
1.03 to 1.81) were associated with increased odds of severity and/or death due to COVID-19.
Neurological manifestations

Smell and taste dysfunctions were reported in 561
(64.3%) included cases at the time of admission (hyposmia: 329/561 or 58.6%; anosmia: 232/561 or 41.4%; dysgeusia: 561/561 or 100%). They were more common
among females (69.7%) than males (OR: 1.46, 95%CI:
1.08 to 1.96) and also more frequent among nonsmokers (66.7%) than smokers (OR: 1.91, 95%CI: 1.32 to
2.77). Co-morbidities were more frequent among cases
with normal smell and taste sensations (OR: 1.42,
95%CI: 1.07 to 1.89). There were 28 cases with rhinorrhea and 17 cases with nasal congestion who reported
loss of smell sensation. Of 561 participants, 142
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individuals (25.3%) reported these symptoms as the first
clinical manifestation. Hyposmia/anosmia and dysgeusia
were found to be associated with reduced odds of severe
cases (OR: 0.69, 95%CI: 0.52 to 0.94) and death (OR:
0.63, 95%CI: 0.39 to 0.95) after adjustment for gender,
age, smoking status, co-morbidity, rhinorrhea, and nasal
congestion (Table 3, Fig. 2).
Myalgia (217/873 or 24.9%), headaches (110/873 or
12.6%), and dizziness (104/873 or 11.9%) were other
common neurological symptoms. The incidence rates of
these conditions were not significantly different among
genders. Of 110 individuals with headaches, 71 cases
(64.5%) had migraine-like episodes; 37 participants
(33.6%) had tension-like headaches; and 2 cases (1.9%)
had only cough-related headaches. Headaches had negative correlation with severity (adjusted OR: 0.52, 95%CI:
0.32 to 0.85) and death due to COVID-19 (adjusted OR:
0.37, 95%CI: 0.75 to 0.92) but myalgia and dizziness
were not associated (Table 3, Fig. 2).
There were 10 cases (1.26%) with COVID-19 who presented cerebrovascular events (Table 4). The mean age
was 63.40 years (SD: 20.55). Brain CT scans were performed in all cases and ischemic stroke was found in 7
patients (70%) and 3 cases (30%) were diagnosed with
ICH. Of cases with ischemic stroke, mild impairment
was observed in 1 case with NIHSS < 5. We found 3
cases with moderate (NIHSS: 5–15), 1 case with moderate to severe (NIHSS: 16–20), and 2 cases with severe
(NIHSS > 21) neurological impairments. The ICH score
of 4 was calculated in 2 cases and the score of 3 was calculated in 1 patient with ICH. Fever (n = 10), cough (n =
8), fatigue (n = 7), myalgia (n = 3), and headaches (n = 1)
were reported in 10.7 ± 2.91 days prior to cerebrovascular events but none were severe COVID-19 cases. Six patients (60%) died in 4.15 ± 2.23 days after hospitalization.
One previously healthy 28 year-old-female was referred
to Loghman hospital with status epilepticus as the sole
clinical manifestation. No history of physical disorders,
head trauma, drug use, or recent respiratory symptoms
was reported from parents. Physical examination revealed bilateral mydriatic and non-reactive pupils with
downward gaze. The EEG showed moderate to severe
diffuse slowing and generalized rhythmic delta activity.

Table 3 The common neurological symptoms among participants
Neurological symptoms

Total

Disease severity

N = 873

Non-severe (N = 574)

Death outcome
Severe (N = 299)

P-value

No
(N = 751)

Yes
(N = 122)

Pvalue

Smell and taste dysfunctions

561 (64.3)

389 (67.8)

172 (57.5)

0.00

496 (66.0)

65 (53.3)

0.00

Myalgia

217 (24.9)

142 (24.7)

75 (25.1)

0.93

190 (25.3)

27 (22.1)

0.50

Headaches

110 (12.6)

86 (15.0)

24 (8.0)

0.00

104 (13.8)

6 (4.9)

0.00

Dizziness

104 (11.9)

75 (13.1)

29 (9.7)

0.16

94 (12.5)

10 (8.2)

0.37

Categorical variables are presented as numbers (percentages)
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Univariable severity

A

B

Multivariable severity

Dizziness: 0.72 (0.46 to 1.12)

Dizziness: 0.68 (0.43 to 1.09)

Myalgia: 0.84 (0.60 to 1.18)

Myalgia: 1.00 (0.71 to 1.40)

Headache: 0.49 (0.30 to 0.79)

Headache: 0.52 (0.32 to 0.85)

Anosmia: 0.64 (0.48 to 0.85)

Anosmia: 0.69 (0.52 to 0.94)

0.0

0.5

1.0

1.5

2.0

0.0

0.5

OR (95% CI)

C

Dizziness: 0.62 (0.30 to 1.25)

Myalgia: 0.83 (0.53 to 1.32)

Myalgia: 0.87 (0.52 to 1.43)

Headache: 0.32 (0.13 to 0.75)

Headache: 0.37 (0.75 to 0.92)

Anosmia: 0.58 (0.39 to 0.86)

Anosmia: 0.63 (0.39 to 0.95)

1.0

2.0

Multivariable Death

D

Dizziness: 0.72 (0.38 to 1.36)

0.5

1.5

OR (95% CI)

Univariable Death

0.0

1.0

1.5

0.0

2.0

0.5

1.0

1.5

2.0

OR (95% CI)

OR (95% CI)

Fig. 2 The prediction of severity and death due to COVID-19 by neurological manifestations

Table 4 Characteristic of participants with cerebrovascular events
Age
(years)

Gender Comorbidities

Type of
event

Localization

NIHSS/ICH
score

Days from first symptom to
event

Death

75

Male

Yes

Ischemic
stroke

Superior cerebellar artery
embolism

4

11

No

18

Female

No

ICH

Left putamen hemorrhage

4

11

Yes

63

Male

Yes

Ischemic
stroke

Left Middle cerebral artery
plaque

24

13

Yes

65

Male

Yes

Ischemic
stroke

Left Middle cerebral artery
plaque

15

8

No

83

Female

Yes

ICH

Right thalamus hemorrhage

3

8

Yes

72

Male

Yes

Ischemic
stroke

Right Middle cerebral artery
plaque

9

7

No

85

Male

Yes

Ischemic
stroke

Left Middle cerebral artery
plaque

23

8

Yes

38

Female

Yes

ICH

Left putamen hemorrhage

4

13

Yes

68

Female

Yes

Ischemic
stroke

Right Middle cerebral artery
plaque

17

12

Yes

67

Male

No

Ischemic
stroke

Right Middle cerebral artery
plaque

10

16

No
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She was intubated and received intravenous levetiracetam (3000 mg) and generalized tonic-clonic seizure occurred within 2 h of drug administration. Intravenous
midazolam was, then, added. No other convulsive seizures were developed during hospitalization. Bilateral
ground glass opacities were observed in chest CT and
the RT-PCR test for COVID-19 was positive. Cerebrospinal (CSF) analysis showed clear appearance with no
cells, protein: 79 mg/dl (normal: 15–45), glucose: 135
mg/dl (normal: 45–80), and opening pressure: 22
cmH2O (normal: 6–25). The PCR panel of CSF was
negative for herpes simplex and no bacterial or fungal
organisms were detected. Other laboratory data showed
thrombocytopenia (n = 43,000) at the time of admission
but other tests were in normal limits (leukocytes: 5.1 ×
103/μL, Na: 142, K: 4.4, Ca: 9.4, Albumin: 3.4, and Mg:
2.1). Urine toxicology analysis for methanol, methadone,
benzodiazepines,
cannabinoids,
methamphetamine,
tramadol, and opiates were negative. The primary brain
CT scans showed no specific abnormalities but the top
of basilar infarction was observed after ten days of
hospitalization (Fig. 3 a, b). The patient died 16 days
after admission.
Follow-up

There were 442 individuals with hyposmia/anosmia and
dysgeusia who survived from COVID-19 and completed
the study. It was found that after 4 weeks of discharge,
209 cases (47.3%) fully recovered from these conditions;
181 cases (40.9%) had partial improvements; and 52
cases (11.8%) reported no changes in their smell and
taste dysfunctions. The full recovery was reported in 302
individuals (68.3%) after 8 weeks of discharge and partial
improvements were found among 119 participants
(26.9%). Twenty one cases (4.8%) with hyposmia (n = 15)
and anosmia (n = 6) reported no changes (Fig. 4). Intermittent parosmia (distortion of odor perception when an
odor is present) was reported in 42 cases (9.5%) after 4
weeks and 137 cases (30.9%) after 8 weeks of discharge.
Intermittent phantosmia (odor perception in the absence
of odor stimulus) was also reported in 11 cases (2.5%)
after 4 weeks and 40 cases (9.0%) after 8 weeks of discharge (Fig. 4). These events occurred in 86 cases
(48.6%) with recovered hyposmia/anosmia, 83 cases
(46.9%) with partial improvements, and eight case (4.5%)
with no smell and taste improvements.
Headaches were reported among 37 of 689 individuals
after 4 weeks of discharge (5.3%) (28 cases with
migraine-like and 9 cases with tension-like headaches)
and 14 cases (2.0%) after 8 weeks (11 cases with
migraine-like and 3 cases with tension-like headaches).
These individuals had no prior history of headaches (e.g.
migraine). The severity was mild to moderate and headaches were well-controlled with simple analgesics. No
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functional impairments were reported among affected
individuals due to headaches. There were 21 participants
(3.0%) after 4 weeks and 9 cases (1.3%) after 8 weeks of
discharge with myalgia. Dizziness was also reported
among 9 individuals after 4 weeks that was recovered
after 8 weeks of discharge (Fig. 4).
The follow-up was continued in participants with parosmia, phantosmia, no improvements in smell and taste,
headaches, and myalgia (Fig. 4). The full recovery was
reported in 9 cases (6.6%) with parosmia, 3 cases (5.0%)
with phantosmia, 2 cases (9.5%) with no prior changes
in smell and taste sensations, 9 cases (64.3%) with headaches, and 4 cases with myalgia (44.4%) after 8 further
weeks of follow-up (16 weeks after discharge). Partial improvements were reported in 64 cases (46.7%) with parosmia, 12 cases with phantosmia (30.0%), and 7 cases
(33.3%) with no prior changes in smell and taste sensations after 16 weeks of discharge. The remaining cases
with headaches had mild migraine-like episodes.

Demyelinating myelitis

One 43-year-old-male visited Loghman hospital after 16
days of prior admission with weakness, paresthesia, and
paresis of upper and lower limbs. The patient also developed low abdominal pain with urinary retention. No history of similar symptoms and neurological disorders
were reported. The initial manifestations due to
COVID-19 were fever, fatigue, myalgia, and headaches
that were recovered after discharge. Neurological examinations showed reduced forces of upper (4 / 5) and
lower limbs (2 / 5). The deep tendon reflexes of all extremities were normal (1+) and Babinski’s sign was
present. The position, vibration, and light tough sensations were impaired in lower limbs. The laboratory data
including leukocyte count, CRP, and LDH were normal.
The CSF analysis showed clear appearance with no cells,
protein: 60 mg/dl, glucose: 43 mg/dl, and opening pressure: 18 cmH2O. The PCR panel of CSF was negative for
herpes simplex and no bacterial or fungal organisms
were detected. The CSF was assessed to detect anti-Nmethyl-D-aspartate (NMDA) antibody, oligoclonal band,
aquaporin-4 receptor (AQP-4), and myelin oligodendrocyte glycoprotein (MOG) antibodies which were negative. Serological testing for the anti-nuclear antibody,
anti-phospholipid antibodies, neuromyelitis optica, antiNMDA, AQP-4, and MOG antibodies was also negative.
The brain and spinal cord MRI showed bilateral thalamic hypersignal lesions (Fig. 3c) with longitudinally extensive transverse myelitis at cervical and thoracic cord
levels (Fig. 3 d, e). The patient was diagnosed with postinfectious demyelinating myelitis and managed with
intravenous immunoglobulin (IVIG) for 7 days. Our patient was discharged from hospital after 16 days with
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Fig. 3 Brain imaging of individuals with status epilepticus (a, b) and demyelinating myelitis (c, d, e)

significant improvements in forces of upper (5 / 5) and
lower limbs (4 / 5).
Guillain-Barré syndrome (GBS)

A 46-year-old-female visited Imam Hossein hospital
after 21 days of prior admission with weakness and
paresthesia of upper and lower limbs as well as bilateral
facial paralysis. The initial symptoms due to COVID-19
were fever and dry cough that were recovered after discharge. Neurological examination showed decreased
forces of upper (4 / 5) and lower limbs (3 / 5) with mild
bilateral peripheral facial nerve palsy. The deep tendon
reflexes of all extremities were absent. The CSF analysis
showed no cells, protein: 93 mg/dl, glucose: 15 mg/dl,

and opening pressure: 18 cmH2O. The EMG-NCV was
conducted and acute axonal motor neuropathy (AMAN)
variant of GBS was diagnosed. The motor nerve conduction and F-wave response were measured on the median,
ulnar, tibial, and peroneal nerves. The sensory nerve
conduction was measured using median, ulnar, and sural
nerves. The normal NCV without evidence of conduction block, and normal sensory nerve action potential
(SNAP) amplitude along with reduced compound
muscle action potential (CMAP) amplitude were found
in both upper and lower extremities. The electromyographic findings were reduced voluntary recruitment
and increased insertional activity. The patient was
treated with five consequent days of IVIG but the
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Fig. 4 Number of participants with neurological symptoms during follow-up

disease progressed and she developed dyspnea and was
intubated. Arrhythmia due to autonomic dysfunction
was also developed and pacemaker was inserted. The
IVIG was used for further 7 days. The symptoms improved gradually and the patient was discharged after
42 days of hospitalizations with improvements in forces
of lower limbs (4 / 5).

Discussion
The COVID-19 is the third outbreak of coronaviruses
after SARS and MERS, which occurred in 2002 and
2012; respectively. The SARS and MERS diseases led to
less than 2000 deaths but the current pandemic outbreak of COVID-19 has claimed more than one million
lives in less than a year. All three viruses were found to
involve vital organ systems including nervous system
[22–24]. The incidence of neurological manifestations
was assessed in our study among hospitalized individuals
with positive RT-PCR of SARS-CoV-2. The smell and
taste dysfunctions were the third most common symptoms in our cases after fever and cough. It was identified
that about two-third of our participants experienced
smell and taste dysfunctions that resolved partially or
completely in 98% of cases after 16 weeks of discharge
from hospital. Myalgia (25%), headaches (13%), dizziness
(12%), and cerebrovascular events (1%) were also reported in participants. Three individuals presented status
epilepticus, post-infectious demyelinating myelitis, and
AMAN variant of GBS.
The involvement of nervous system in COVID-19 disease can be attributed to the direct invasion of virus or
secondary para-infectious mechanisms. The SARS-CoV2 was found to enter the human cells using angiotensin
converting enzyme 2 (ACE2) receptors [25] that can be
expressed on nasal goblet and ciliated epithelial cells as

well as oligodendrocytes [26, 27]. The detection of the
SARS-CoV-2 in the CSF of cases with encephalopathy
[28, 29] and demyelinating disorder [30] was an important clue to show that the virus could be neuroinvasive.
Furthermore, viral particles were found in the brain tissue of cases with the COVID-19 disease [31, 32]. It
should be noted that these results should be interpreted
with caution [33]. Small numbers of cases were identified and some studies reported no evidence of the
SARS-CoV-2 detection in the CSF or brain tissue of
confirmed COVID-19 cases with neurological symptoms
[34, 35]. The hyper-inflammatory state due to overproduction of cytokines (e.g. interleukin-6 and tumor
necrosis factor) also known as “cytokine storm” was reported to be another plausible underlying mechanism of
neuronal damage in COVID-19 disease [36].
Several studies reported that hyposmia/ anosmia and
dysgeusia were about 20 to 98% prevalent among confirmed cases with COVID-19 [7, 8, 37–39]. The discrepancies in results can be due to the methodological
differences. The study design, sample size, recruitment
setting (inpatients vs. outpatients), and model of testing
smell sensation (self-reporting survey vs. physical exam)
could significantly affect the results. It was found that
anosmia was more common in non-hospitalized individuals than hospitalized ones with COVID-19 [40, 41].
Our study showed that loss of smell and taste was associated with reduced odds of severe cases and death due
among hospitalized cases. A recent study on 576 inpatients also demonstrated that cases with anosmia had
lower mortality rate and less severe course of the disease
[42]. The follow-up of individuals with the COVID-19
and hyposmia/ anosmia was assessed in few studies. An
observational cohort study reported that over 70% of
cases with smell and taste dysfunctions had early

Amanat et al. BMC Neurology

(2021) 21:116

improvements after 4 weeks of onset of anosmia [43].
The recovery in all cases was reported in another study
in 28 days [44]. A 6-month follow-up study on 434 individuals showed that over 70% had full or almost full recovery of loss of smell and about 2% of cases reported
no improvements [45]. It was also reported that over
40% of participants developed parosmia with the median
interval of 2.5 months after the onset of smell dysfunction [45]. Our study also showed that about 10% of cases
with hyposmia/anosmia developed parosmia after 4
weeks of discharge that increased to over 30% after 8
weeks. Longer follow-up periods are needed to assess
the prognosis of altered smell functions.
A systematic literature review estimated that myalgia
(28.5%) and headaches (14%) were common manifestations of COVID-19 [46]. In consistent with this study, it
was previously found that headaches were independent
predictors of lower risk of mortality among hospitalized
cases [47]. We found that migraine-like episodes were
the most frequent phenotype of headaches among the
participants. A recent study also showed that headaches
were common manifestations in COVID-19 and they
were mostly presented as bilateral severe headaches at
the time of admission with migraine phenotype [48] Individuals who diagnosed with COVID-19 were found to
be at 0.5 to 1.3% risk of subsequent cerebrovascular
events including ischemic stroke, ICH, and cerebral venous thrombosis [10, 49]. It was reported that among individuals with COVID-19 and stroke, older age, higher
baseline NIHSS, and cryptogenic stroke were associated
with early mortality [50].
To date, few cases with post-infectious demyelinating
conditions of the central nervous system (CNS) after the
COVID-19 disease were diagnosed [13, 51]. The structure and replication of SARS-CoV-2 was reported to be
similar with mouse hepatitis virus (MHV) [52]. The
MHV was found to remain in mouse CNS after acute infection and could induce an immune-mediated, chronic
demyelinating disease, similar to multiple sclerosis in
humans [33, 53]. We found two individuals with the
CNS demyelination in our medical centers (51, present
study) during COVID-19 pandemic outbreak. Future
longitudinal studies should assess the prevalence of these
events in confirmed COVID-19 cases. The postinfectious demyelination of peripheral nervous system
was also reported after recovery from COVID-19 disease. The GBS is a relatively rare disease with the incidence ranged from 0.81 to 1.89 per 100,000 person-years
[54]. Of 873 hospitalized individuals in our study, one
case developed AMAN variant of GBS. Another study
with 1200 patients also reported the incidence of 0.4%
for GBS [55]. Systematic review studies reported that the
majority of cases with COVID-19 and GBS had acute inflammatory demyelinating polyradiculopolyneuropathy
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(AIDP) variant [56, 57]. The facial nerve palsy that was
observed in our participant was also found in about half
of the prior reported cases [56].
To our knowledge, this was the first multi-center prospective study assessed the course of different neurological manifestations associated with COVID-19
disease. The prospective design of the study could reduce the possible information bias. The study was also
multi-center that can increase the external validity.
There were some limitations to our study. Some symptoms including anosmia and dysgeusia are often underreported by patients with severe disease and our results
could be affected by this measurement bias. Participants
were sampled from hospitals rather than community
(hospital based vs. population based studies). This can
lead to selection bias (Berkson’s bias); as many individuals with mild severity were not included in our study.
A short period of follow-up and lacking control group
were other major limitations that should be resolved in
future studies. Some neurological symptoms (e.g. smell
and taste sensations, headaches, and myalgia) were not
objectively assessed and were reliant on individuals’ reports. Further studies should be conducted to assess the
incidence of CNS demyelinating events and evaluate the
course of altered smell sensation including parosmia and
phantosmia.

Conclusions
Neurological symptoms are prevalent among individuals
with the COVID-19 and should not be under-estimated
during the current pandemic outbreak. The smell and
taste dysfunctions and headaches were common neurological symptoms that were associated with less severe
cases and lower mortality rates.
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